News

The FDA has expanded the use of efgartigimod alfa-fcab and Hytrulo to include adults with AChR-Ab seronegative generalized myasthenia gravis, marking the first approved FcRn-targeted therapy for this patient population.

The FDA approval of ocrelizumab for pediatric RRMS expands access to a high-efficacy anti-CD20 therapy for children and adolescents with historically limited treatment options.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 8, 2026.

The FDA extended review of Eisai and Biogen’s supplemental filing for once-weekly subcutaneous lecanemab initiation in early Alzheimer disease, with a new decision date set for August 2026 amid ongoing evaluation of additional submitted data.

In this episode, Mitzi Joi Williams, MD, and Jacqueline Rosenthal, MD, review the past year in multiple sclerosis, highlighting emerging therapies, biomarkers, and evolving approaches to personalized, comprehensive care.

MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Tamara Kaplan, MD. [LISTEN TIME: 36 minutes]

Adam Vogel, PhD, Professor of Speech Neuroscience at The University of Melbourne and Chief Science Officer at Redenlab, discusses the emerging role of speech analytics as an objective, scalable biomarker in neurodegenerative disease research.

David Setboun, PharmD, MBA, CEO of PharmatrophiX, and Frank Longo, MD, PhD, Co-founder & Chairman, discuss LM11A-31’s upstream mechanism targeting p75 signaling and its potential to modify neurodegenerative disease biology.

The pediatric neurologist at Johns Hopkins Medicine provided commentary on the FDA's decision, and also discussed the evolving SMA treatment landscape in general terms. [WATCH TIME: 11 minutes]

The director of the Center for Neurological Restoration at Cleveland Clinic commented on tavapadon’s D1-selective mechanism, clinical development, and potential role in treating Parkinson disease across stages. [WATCH TIME: 4 minutes]

Bill Nye, science educator and advocate, reflects on Friedreich ataxia awareness, diagnostic challenges, and the evolving role of genetics and communication in advancing care.

Srikanth Muppidi, MD, a clinical professor of adult neurology at Stanford University, discussed phase 2 findings from the KYSA-6 trial of mivocabtagene autoleucel (miv-cel; KYV-101) in MG.

In honor of Huntington Disease Awareness Month, held annually in May, the director of the Huntington's Disease Center at Northwestern Medicine discussed the design of the INVEST-HD trial.

First-time seizures were associated with more than a 5-fold increase in short-term cancer risk and persistent long-term risk in a nationwide cohort study of nearly 50,000 adults.

Amanda Piquet, MD, FAAN, spoke about data she presented at AAN's 2026 Meeting.

The director of the Neuromuscular Division at the Medical University of South Carolina shared post hoc CHAMPION-MG trial findings at MDA 2026, suggesting ravulizumab may enable corticosteroid reduction while maintaining or improving clinical outcomes. [WATCH TIME: 4 minutes]

Clene plans to pursue accelerated FDA approval for CNM-Au8 in ALS based primarily on neurofilament light biomarker data and phase 2 studies, with a confirmatory phase 3 trial expected to follow.

Following his symposium at the 2026 AAN Annual Meeting, science educator Bill Nye discussed his connection to Friedreich ataxia, emphasizing the importance of awareness, early diagnosis, and effective communication between clinicians and patients. [WATCH TIME: 4 minutes]

Aprill Lane, US Advocacy Lead for Rare Disease at UCB, discusses a new national initiative aimed at improving nutrition access and reducing daily disease burden for patients with myasthenia gravis.

The associate chief quality officer at Nationwide Children’s Hospital discussed how AI-driven research initiatives within PERC are helping identify missed epilepsy diagnoses and improve care pathways in pediatric populations. [WATCH TIME: 3 minutes]

New phase 2 data indicate that dazucorilant may reduce mortality risk in amyotrophic lateral sclerosis, with sustained effects observed through 2 years, although no significant improvement in functional outcomes was reported.

GLP-1 receptor agonists show growing relevance in neurology, with strongest evidence in stroke prevention and obstructive sleep apnea and emerging signals in idiopathic intracranial hypertension and migraine.

Here's some of what is coming soon to NeurologyLive® this week.

Neurologist Michael Levy, MD, PhD, outlines phase 3 METEOROID findings demonstrating satralizumab’s ability to reduce relapse risk and provide early, sustained disease control in patients with MOGAD.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is dyskinesia treatment options!

Single-patient study reports reductions in Alzheimer-related biomarkers following dapsone-based therapy for chronic Lyme disease, highlighting a potential but unproven infection–neurodegeneration link.

Neurology News Network for the week ending May 2nd, 2026. [WATCH TIME: 5 minutes]

Interim results from the PIVOT-HD extension study suggested dose-dependent effects of votoplam on measures of disease progression in stage 2 Huntington disease compared with a natural history cohort.